Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SA-691
- Development stage
- Unknown
- Lead developer
- Allero Therapeutics
- Administration
- Oral
01
Overview
SA-691 is a discovery-stage therapeutic candidate being developed by Allero Therapeutics. It is characterized as a platform application, likely utilizing the company's proprietary Sequential Oral Mucosal Immunotherapy (SOMIT) technology. The SOMIT platform is designed to treat immune-mediated conditions by delivering specific antigens along with Toll-like receptor binding proteins (TBPs) via an oral mucosal patch to induce immune tolerance. While Allero Therapeutics has disclosed other candidates for celiac disease and food allergies, the specific molecular targets and primary indications for SA-691 remain proprietary and have not yet been publicly detailed.
Beyond the preview
Go deeper on SA-691.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SA-691.